Innovus Pharmaceuticals Inc. (fka INNV)

[BooDog]

Seems to me, right now, the company is in the "go big and get big" stage. Amended S-1/a out this morning.
http://ih.advfn.com/p.php?pid=nmona&article=74097998


Our Products

We currently generate revenue from 17 products in the U.S. and six in international countries, as follows:

1. Vesele ® for promoting sexual and health (U.S. and U.K.);

2. Zestra ® for female arousal (U.S., U.K., Denmark, Canada, Morocco, the UAE and South Korea);

3. Zestra Glide ® (U.S, Canada and the MENA countries);

4. EjectDelay ® indicated for the treatment of premature ejaculation (U.S. and Canada);

5. Sensum+ ® to alleviate reduced penile sensitivity (U.S., U.K. and Morocco);

6. Beyond Human ® Testosterone Booster;

7. Beyond Human ® Ketones;

8. Beyond Human ® Krill Oil;

9. Beyond Human ® Omega 3 Fish Oil;

10. Beyond Human ® Vision Formula;

11. Beyond Human ® Blood Sugar;

12. Beyond Human ® Colon Cleanse;

13. Beyond Human ® Green Coffee Extract;

14. Beyond Human ® Growth Agent;

15. RecalMax ™ for brain health;

16. Androferti ® (U.S. and Canada) for the support of overall male reproductive health and sperm quality; and

17. UriVarx ™ for overactive bladder and urinary incontinence.

10K excerpt
Net Revenue
We recognized net revenue of approximately $4.8 million for the year ended December 31, 2016 compared to $0.7 million for the year ended December 31, 2015. The increase in revenue in 2016 was primarily the result of the product sales generated through the sales and marketing platform acquired in the Beyond Human® asset acquisition. The increase was also due to an increase in sales of Vesele® and Sensum+® which generated net revenue of approximately $2.2 million and $0.4 million during the year ended December 31, 2016, respectively, compared to approximately $7,000 and less than $1,000 during the year ended December 31, 2015, respectively. We generated additional net revenue of approximately $0.8 million and $0.2 million when selling Vesele® and Sensum+® with other Beyond Human® products during the year ended December 31, 2016, respectively. The increase in net revenue from the sale of products through the Beyond Human® sales and marketing platform was offset by decreases in our other existing product sales channels to major retailers and wholesalers as we concentrated our sales efforts and resources on integrating our existing products into the Beyond Human® sales and marketing platform. The decreases in existing product sales channels resulted in net revenue from the Zestra® products decreasing approximately $0.3 million during the year ended December 31, 2016 when compared to the same period in 2015. We signed an exclusive licensed and distribution agreement in November 2016 which is expected to lead to an increase in product sales of Zestra® and Zestra Glide® through that sales channel in 2017.
https://www.sec.gov/Archives/edgar/data/1411879/000165495417001819/innv_10k.htm


In addition, we currently expect to launch in the U.S. the following products in 2017, subject to the applicable regulatory approvals, if required:



1. Xyralid™ for the relief of the pain and symptoms caused by hemorrhoids (first half of 2017);

2. AllerVarx ™ for allergic rhinitis symptoms (first half of 2017);

3. AndroVit™ for prostate and sexual health (second half of 2017);

4. Urocis™ XR for urinary tract infections in women (second half of 2017); and

5. FlutiCare ™ for allergic rhinitis subject to FDA ANDA approval (second half of 2017).

Great to see the product line growing. Don't hold back, a wee bit of dilution to bring in more revenue and keep the company growing. A strategy, yet fundamentally difficult to swallow short term until it pays off in the end. Likely with a A/S increase sooner than later. Just an opinion based on the authorized and the soon to be new outstanding fully converted. Just my opinion.